Fuda Cancer Hospital
Fuda Cancer Hospital
China, Cantão
| China | Turki | Austria | |
| Kriodestruksi | dari $6,200 | dari $3,500 | dari $4,000 |
| Bedah mikro Mohs | dari $2,400 | dari $2,200 | dari $4,000 |
| Eksisi luas melanoma | dari $4,500 | dari $4,000 | - |
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Mohs micrographic surgery is not widely available in all Chinese hospitals. It is highly concentrated in JCI-accredited facilities and top-tier oncology hubs in Beijing, Shanghai, and Guangzhou. Specialized centers like Fuda Cancer Hospital offer micrographic tumor tracking for complex facial basal cell carcinoma cases.
Bookimed Expert Insight: While patients often search specifically for Mohs surgery by name, Bookimed data shows that Xiamen Humanity Hospital and other large tertiary centers treat over 1,000,000 patients annually using oncologic plastic surgery. When exact Mohs terminology is not used, asking for frozen-section margin control often identifies the same high-precision, tissue-sparing results for facial lesions.
Patient Consensus: Patients emphasize going to the largest possible university or cancer center for facial tumors. They notes it is vital to confirm both tumor removal and reconstructive plastic surgery are available at the same hospital.
Reconstructive options in China after Basalioma excision include local skin flaps, full-thickness grafts, and microsurgical free flaps. Chinese oncology centers utilize a reconstructive ladder approach. Surgeons prioritize matching skin texture and preserving vital functions like eyelid closure. JCI-accredited facilities often perform these procedures.
Bookimed Expert Insight: Data from major Chinese tertiary centers like Xiamen Humanity Hospital shows a massive scale of operations, with around 1,000,000 patients treated annually. This high volume allows surgical teams to specialize in niche reconstructions. For example, Dr. Liu Shi Xin at Xiamen focuses on precise tumor management. Patients often find that specialized oncology hospitals provide more integrated care than general plastic surgery clinics. This ensures clear margins before the final reconstruction begins.
Patient Consensus: Patients emphasize that preserving functions like blinking or nasal airflow is more important than a perfect scar. Many note that flap surgery usually looks more natural than skin grafts for facial repairs.
Patients can receive non-surgical treatments like photodynamic therapy and cryotherapy for basalioma in China. These therapies are available at JCI-accredited cancer centers and large tertiary hospitals. Specialists often reserve these options for superficial lesions or patients unable to undergo traditional surgery.
Bookimed Expert Insight: While many general hospitals offer cryotherapy, international patients benefit from choosing oncology-specific centers like Fuda Cancer Hospital. This facility focuses on minimally invasive therapies instead of standard chemotherapy for advanced cases. Their JCI accreditation confirms they meet global safety standards for complex procedures like cryosurgery and NanoKnife.
Patient Consensus: Patients note that while non-surgical options are available, doctors often recommend surgery first for better precision. It is important to confirm the pathology subtype as these treatments work best for superficial lesions.
Odomzo (sonidegib) is the primary targeted systemic therapy approved in China for advanced basal cell carcinoma. The National Medical Products Administration (NMPA) cleared this oral Hedgehog inhibitor specifically for adult patients with locally advanced disease who cannot undergo surgery or radiation.
Bookimed Expert Insight: Xiamen Humanity Hospital is a tertiary facility accredited for Phase I–IV drug trials. This is crucial for advanced cases. If standard therapies like sonidegib fail, these accredited centers provide legal pathways to clinical trials for next-generation Hedgehog inhibitors.
Patient Consensus: Patients note that drug approval does not always guarantee immediate hospital availability. They recommend checking the specific pharmacy formulary at large cancer centers before traveling for treatment.
International patients choose China for Basalioma care to access advanced non-invasive therapies and high-volume oncology centers. Specialized facilities utilize cryodestruction and targeted molecular therapies. These centers provide rapid scheduling for complex cases. Many institutions hold JCI accreditation for safety.
Bookimed Expert Insight: China's oncology landscape is defined by massive scale and specialized research hubs. Xiamen Humanity Hospital serves 1,000,000 patients annually and manages Phase I-IV drug trials. This high volume allows surgeons like Dr. Liu Shi Xin to gain deep expertise in precision radiotherapy for complex malignancies. Patients benefit from this concentrated clinical experience which is rarely matched in smaller regional healthcare systems.
Patient Consensus: Patients value the rapid transition from initial assessment to surgery in modern tertiary hospitals. They emphasize the importance of confirming the pathology reporting process and arranging English-speaking support before arrival.